Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WFJHW
ADC Name
BAT-8009
Synonyms
BAT 8009; BAT8009; B7-H3-ADC
   Click to Show/Hide
Organization
Bio-Thera Solutions, Ltd.
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Antibody Name
Undisclosed
Antigen Name
CD276 antigen (CD276)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05405621
Phase 1
A phase 1, multi-center, open-label study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT8009 in patients with advanced solid tumours.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05405621  Clinical Status Phase 1
Clinical Description A phase 1, multi-center, open-label study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of BAT8009 in patients with advanced solid tumours.
References
Ref 1 A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT8009 in Patients With Advanced Solid Tumours, NCT05405621

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.